Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 5/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | QDPR | P09417 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 3/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17514308 | 0.98 | HTR2C (0.50) | SLC18A3SIGMAR1HTR2CPLATPTGS2 | |
| SCHEMBL13176976 | 0.86 | PTGS2 (0.51) | PTGS2ENPP2 | |
| SCHEMBL469038 | 0.82 | LMNA (0.56) | PTGS2ENPP2 | |
| SCHEMBL12473626 | 0.82 | LMNA (0.51) | PTGS2ENPP2 | |
| SCHEMBL22324769 | 0.82 | SLC18A3 (0.48) | SLC18A3SIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL9827832 | 0.81 | SLC18A3 (0.52) | SLC18A3SIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL5694991 | 0.81 | SLC18A3 (0.52) | SLC18A3SIGMAR1HTR2CQDPRHTR6 | |
| SCHEMBL26354332 | 0.81 | LMNA (0.59) | PTGS2 | |
| SCHEMBL10182153 | 0.81 | LMNA (0.59) | PTGS2 | |
| SCHEMBL17117325 | 0.81 | HTR2C (0.50) | SLC18A3SIGMAR1HTR2CQDPRHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023062049-A1 | HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-20 | — | — | WO | disclosed |
| WO-2022125925-A1 | COMPOSITIONS FOR TREATING DRY AGE-RELATED MACULAR DEGENERATION (AMD) | COGNITION THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2016027284-A2 | PIPERIDINE UREAS AS CATHEPSIN CYSTEINE PROTEASE INHIBITORS | ALKEM LABORATORIES LTD. (IN) | 2016-02-25 | — | — | WO | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090105305-A1 | Therapeutic Agents - 550 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| CN-101252929-A | G protein-coupled receptor agonists | PROSIDION LTD (GB) | 2008-08-27 | — | — | CN | disclosed |
| WO-2008075070-A1 | SULFONAMIDE DERIVATIVES FOR THERAPEUTIC USE AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008059214-A1 | BISAMLDE DERIVATIVES AND USE THEREOF AS FATTY ACID SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| EP-1909791-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105305-A1 | Therapeutic Agents - 550 | FABP4, GPR119, FASN | SLC18A3 4645/4885SIGMAR1 4037/4885HTR2C 4806/4885 |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | SLC18A3 1217/4885SIGMAR1 487/4885HTR2C 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.